Brief: Immix Biopharma Announces Positive Interim Data In Early-To-Mid-Stage Cancer Drug Trial
03/05/2023 15:04
May 3 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA ANNOUNCES EARLY POSITIVE IMX-110 INTERIM
CLINICAL TRIAL DATA DEMONSTRATING 100% TUMOR SHRINKAGE IN
ADVANCED METASTATIC COLORECTAL CANCER AT THE LOWEST DOSE OF
IMX-110 + BEIGENE / NOVARTIS ANTI-PD-1 ANTIBODY TISLELIZUMAB
Source text for Eikon: ID:nGNX14x35x
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary